Free tool
FAERS Monitor: Rocaltrol
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021068 or its brand name (Rocaltrol, Calcitriol). Reports on generic versions are filed under their own applications.
Reports
20,257
Serious
15,687
77% of reports
Hospitalization
8,629
Death reported
2,692
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea1,470
- diarrhoea1,194
- off label use1,162
- chronic kidney disease1,115
- vomiting1,109
- dyspnoea1,099
- renal failure1,058
- fatigue1,050
- acute kidney injury973
- death908
- drug hypersensitivity882
- drug ineffective801
- abdominal pain789
- headache768
- asthenia766
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 179 |
| 2005 | 245 |
| 2006 | 171 |
| 2007 | 190 |
| 2008 | 282 |
| 2009 | 388 |
| 2010 | 392 |
| 2011 | 400 |
| 2012 | 513 |
| 2013 | 525 |
| 2014 | 541 |
| 2015 | 863 |
| 2016 | 1,153 |
| 2017 | 1,378 |
| 2018 | 1,728 |
| 2019 | 2,327 |
| 2020 | 1,542 |
| 2021 | 1,449 |
| 2022 | 1,158 |
| 2023 | 1,212 |
| 2024 | 1,417 |
| 2025 | 1,212 |
| 2026 | 992 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,033,902 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic kidney diseaseSignal | 1,115 | 15.4 | 14.6 | 14,886 |
| renal failureSignal | 1,058 | 8.3 | 7.9 | 6,806 |
| acute kidney injurySignal | 973 | 6.6 | 6.2 | 4,658 |
| drug hypersensitivitySignal | 882 | 4.7 | 4.5 | 2,619 |
| abdominal painSignal | 789 | 3.5 | 3.3 | 1,439 |
| vomitingSignal | 1,109 | 2.5 | 2.3 | 972 |
| astheniaSignal | 766 | 2.1 | 2.0 | 458 |
| dyspnoeaSignal | 1,099 | 2.0 | 1.9 | 578 |
| nausea | 1,470 | 1.9 | 1.8 | 683 |
| diarrhoea | 1,194 | 1.9 | 1.8 | 543 |
| fatigue | 1,050 | 1.4 | 1.3 | 124 |
| off label use | 1,162 | 1.4 | 1.3 | 125 |
| headache | 768 | 1.3 | 1.2 | 46 |
| death | 908 | 1.1 | 1.0 | 8 |
| drug ineffective | 801 | 0.6 | 0.6 | 184 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.